Holen Sie sich die Stockscreener-App
1.33
8.13%
0.10
Vorhandelsmarkt:
1.35
0.02
+1.50%
Schlusskurs vom Vortag:
$1.23
Offen:
$1.25
24-Stunden-Volumen:
3.33M
Relative Volume:
1.38
Marktkapitalisierung:
$109.42M
Einnahmen:
$65,300
Nettoeinkommen (Verlust:
$-84.95M
KGV:
-0.688
EPS:
-1.9332
Netto-Cashflow:
$-88.92M
1W Leistung:
-2.21%
1M Leistung:
+17.70%
6M Leistung:
-24.43%
1J Leistung:
-32.83%
1-Tages-Spanne:
$1.22
$1.34
1-Wochen-Bereich:
$1.20
$1.445
52-Wochen-Spanne:
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Firmenname
Inovio Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 410-3134
Adresse
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.33 | 101.20M | 65,300 | -84.95M | -88.92M | -1.9332 |
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.59 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.51 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.73 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-01-25 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-11-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Fortgesetzt | Jefferies | Hold |
| 2021-09-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Eingeleitet | Jefferies | Hold |
| 2021-03-23 | Eingeleitet | BofA Securities | Neutral |
| 2021-02-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-17 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Hochstufung | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-07-01 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-21 | Eingeleitet | The Benchmark Company | Buy |
| 2020-04-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
| 2017-10-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-06 | Eingeleitet | Citigroup | Buy |
| 2017-06-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Bestätigt | Maxim Group | Buy |
| 2017-03-16 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
Alle ansehen
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits
ApolloBio reports positive phase 3 results for VGX-3100 in China - Investing.com UK
Positive Phase 3 Results for Inovio (INO) Partnered VGX-3100 in China - GuruFocus
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio (NASDAQ: INO) director awarded RSUs and 41,800 options - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Inovio (NASDAQ: INO) grants RSUs and stock options to director Ann Calby Miller - Stock Titan
Equity grants to Inovio (NASDAQ: INO) director David Weiner disclosed - Stock Titan
Inovio (NASDAQ: INO) director receives RSUs and stock options grant - Stock Titan
Inovio (NASDAQ: INO) director granted 34,200 RSUs and 41,800 options - Stock Titan
INOVIO (INO) Chief Scientific Officer reports RSU vesting, tax withholding and new stock option awards - Stock Titan
Inovio (INO) CMO granted RSUs and 46,876 stock options at $1.73 - Stock Titan
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China - PR Newswire
Inovio (INO) CFO granted stock options, RSUs and reports RSU vesting - Stock Titan
Inovio (NASDAQ: INO) CEO receives new RSUs and options as shares withheld for taxes - Stock Titan
Inovio Shareholders Endorse Governance Changes and Leadership - TipRanks
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Inovio (NASDAQ: INO) overhauls board roles and wins approval on all 2026 shareholder proposals - Stock Titan
Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who L - GuruFocus
$Moderna (MRNA.US)$ $Inovio Pharmaceuticals (INO.US)$ $3M (MMM.US)$ - Moomoo
Earnings call transcript: Inovio beats Q1 2026 EPS forecast but stock slips - Investing.com UK
Earnings call transcript: Inovio beats Q1 2026 EPS forecast but stock slips By Investing.com - Investing.com South Africa
Inovio Stock Price Today | NASDAQ: INO Live - Investing.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio (NASDAQ: INO) CEO nets shares from RSU vesting and tax withholding - Stock Titan
Inovio Pharmaceuticals (INO) CFO exercises 4,771 RSUs and has 2,571 shares withheld for taxes - Stock Titan
INOVIO (NASDAQ: INO) CSO settles RSUs, shares withheld for tax - Stock Titan
INOVIO (NASDAQ: INO) CMO vests RSUs and withholds shares for taxes - Stock Titan
Inovio Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:INO) 2026-05-16 - Seeking Alpha
INO Should I Buy - Intellectia AI
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2026 Earnings Call Transcript - Insider Monkey
Highbridge reports 6.19M warrant‑issued shares in Inovio (INO) - Stock Titan
Investigation Alert: Investors who hold shares of Inovio - openPR.com
INOVIO Shares Drop 10% After Discounted $25 Million Public Offering - MSN
Inovio Pharmaceuticals stock (US45773H2013): Q1 2026 results and INO-3107 FDA review - AD HOC NEWS
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms (NASDAQ:INO) - Seeking Alpha
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
INOVIO Reports First Quarter 2026 Financial Results and Recent B - GuruFocus
Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in Advancing INO-3107 - GuruFocus
Inovio outlines cash runway into Q1 2027 as INO-3107 targets October 30, 2026 PDUFA date - MSN
Inovio and Fossil Q1 results highlight strategic progress - MSN
Salt Lake City Topic INOVIO PHARMACEUTICALS, INC. | News, Weather, Sports, Breaking News - KMYU
Earnings call transcript: Inovio’s Q1 2026 highlights clinical progress, stock rises 2.84% - Investing.com UK
Inovio Pharmaceuticals (INO) Q1 2026 Earnings Report Highlights Progress and Cash Position - GuruFocus
Is Inovio Pharmaceuticals (INO) Still 545.2% Overvalued After Q1 - GuruFocus
Inovio (INO) Q1 2026 Earnings Call Transcript - AOL.com
Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Inovio Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Inovio’s Q1 2026 highlights clinical progress, stock rises 2.84% By Investing.com - Investing.com South Africa
Finanzdaten der Inovio Pharmaceuticals Inc-Aktie (INO)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):